Furthermore, changes in AD biomarkers (such as β-amyloid (βA) deposition, Tau phosphorylation, cortical thickness or glucose metabolism in brain) precede clinical AD symptoms by 10–20 years [1,8]. Here, MAPT is linked to Alzheimer disease.